- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Mohan Bangalore, Wyeth
In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients.
Mohan Bangalore
Senior Director and Site Head, Wyeth
In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients. While at GlaxoSmithKline, I helped set up oncology clinical trials in India and China for Tykerb (lapatinib), which is now on the market for treatment of breast cancer. It was gratifying to see the drug I worked on help cancer patients. That moment was decisive, as it exemplifies our ability to improve patients' lives. The experience also opened the door for me to India and China clinical operations.
My major accomplishment at Wyeth has been the establishment of the India Clinical Research Center (ICRC) in Bangalore, through a novel partnership with Accenture. Today, ICRC has some 160 team members supporting core clinical functions such as clinical writing, statistical programming, medical research support, document quality, document technology, and clinical administrative data support. I also provide administrative and operational oversight for ICRC, and identify opportunities across functions and develop strategic solutions with stakeholders.
I look forward to developing new outsourcing models and creating innovative ways for sponsors and service providers to collaborate. One thing I know is that I will continue to make significant contributions to global clinical operations in the pharmaceutical industry. I see myself becoming an industry leader in clinical outsourcing with a special focus on India and China clinical operations.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.
